Browsing by Author "Aljurf, Mahmoud"

Filter results by typing the first few letters
Now showing 1 - 5 of 5
  • No Thumbnail Available
    Item
    Comparable Survival Using A CMV-Matched Or A Mismatched Donor For CMV Plus Patients Undergoing T-Replete Haplo-HSCT With PT-Cy For Acute Leukemia: A Study Of Behalf Of The Infectious Diseases And Acute Leukemia Working Parties Of The EBMT
    (2018) Cesaro, Simone; Crocchiolo, Roberto; Tridello, Gloria; Knelange, Nina; Van Lint, Maria Teresa; Koc, Yener; Ciceri, Fabio; Gulbas, Zafer; Tischer, Johanna; Afanasyev, Boris; Bruno, Benedetto; Castagna, Luca; Blaise, Didier; Mohty, Mohamad; Irrera, Giuseppe; Diez-Martin, J. L.; Pierelli, Luca; Pioltelli, Pietro; Arat, Mutlu; Delia, Mario; Fagioli, Franca; Ehninger, Gerhard; Aljurf, Mahmoud; Carella, Angelo Michele; Ozdogu, Hakan; Mikulska, Malgorzata; Ljungman, Per; Nagler, Arnon; Styczynski, Jan; https://orcid.org/0000-0002-8902-1283; 29330396; AAD-5542-2021
    The role of donor CMV serostatus in the setting of non T-cell depleted haplo-HSCT with post-transplant cyclophosphamide (PT-Cy) has not been specifically addressed so far. Here we analyzed the impact of the donor CMV serological status on the outcome of 983 CMV seropositive (CMV+), acute leukemia patients receiving a first, non T-cell depleted haplo-HSCT registered in the EBMT database. The 1-year NRM was 21.3% (95% CI: 18.4-24.8) and 18.8% (95% CI: 13.8-25.5) in the CMV D+P/R+ and D-/R+ pairs, respectively (p = 0.40). Similarly, 1-year OS was 55.1% (95% CI: 50.1-58.0) and 55.7% (95% CI: 48.0-62.8) in the same groups (p = 0.50). The other main outcomes were comparable. No difference in NRM nor OS was observed after stratification for the intensity of conditioning and multivariate anaysis confirmed the lack of significant association with NRM or OS. In conclusion, the choice of a CMV-seronegative donor did not impair early survival of CMV-seropositive patients with acute leukemia after a first, non T-cell depleted haploidentical HSCT and PT-Cy among this series of 983 consecutive patients. Future research may focus on the assessment of the hierarchy of all the donor variables.
  • No Thumbnail Available
    Item
    Current Use of Androgens in Bone Marrow Failure Disorders: A Report From the Severe Aplastic Anemia Working Party (Saawp) of the Ebmt
    (2023) Pagliuca, Simona; Kulasekararaj, Austin; Eikema, Dirk Jan; Piepenbroek, Brian; Iftikhar, Raheel; Satti, Tariq Mahmood; Griffin, Morag; Laurino, Marica; Kupesiz, Alphan; Bertrand, Yves; Fattizzo, Bruno; Yakoub Agha, Ibrahim; Aljurf, Mahmoud; Corti, Paola; Massaccesi, Erika; Lioure, Bruno; Calabuig, Marisa; Klammer, Matthias; Unal, Emel; Wu, Depei; Chevallier, Patrice; Forcade, Edouard; Snowden, John A.; Ozdogu, Hakan; Risitano, Antonio; de Latour, Regis Peffault
  • No Thumbnail Available
    Item
    Current Use of Androgens in Bone Marrow Failure Disorders: A Report from the Severe Aplastic Anemia Working Party (SAAWP) of the European Society of Blood and Marrow Transplantation (EBMT)
    (2022) Pagliuca, Simona; Kulasekararaj, Austin; Eikema, Dirk-Jan; Piepenbroek, Brian; Iftikhar, Raheel; Satti, Tariq Mahmood; Griffin, Morag; Laurino, Marica; Kupesiz, O. Alphan; Bertrand, Yives; Fattizzo, Bruno; Yakoub Agha, Ibrahim; Aljurf, Mahmoud; Corti, Paola; Massaccesi, Erika; Lioure, Bruno; Calabuig, Marisa; Klammer, Matthias; Unal, Emel; Wu, Depei; Chevallier, Patrice; Forcade, Edouard; Snowden, John A.; Ozdogu, Hakan; Risitano, Antonio; de Latour, Regis Peffault
  • No Thumbnail Available
    Item
    Graft-Versus-Host Disease and Relapse/Rejection-Free Survival After Allogeneic Transplantation for Idiopathic Severe Aplastic Anemia: A Comprehensive Analysis from the SAAWP of the EBMT
    (2023) Devillier, Raynier; Eikema, Dirk-Jan; Dufour, Carlo; Aljurf, Mahmoud; Wu, Depei; Maschan, Alexei; Kulagin, Alexander; Halkes, Constantijn J. M.; Collin, Matthew; Snowden, John; Renard, Cecile; Ganser, Arnold; Sykora, Karl-Walter; Gibson, Brenda E.; Maertens, Johan; Itala-Remes, Maija; Corti, Paola; Cornelissen, Jan; Bornhaeuser, Martin; Colorado Araujo, Mercedes; Ozdogu, Hakan; Risitano, Antonio; Socie, Gerard; de latour, Regis Peffault; 36951165
    Survival after allogeneic hematopoietic stem cell transplantation (allo-HSCT) for severe idiopathic aplastic anemia (SAA) has improved in recent years, approaching 75% at 5 years. However, an SAA-adapted composite endpoint, graft-versus-host disease (GvHD) and relapse/rejection-free survival (GRFS), may more accurately assess patient outcomes beyond survival. We analyzed GRFS to identify risk factors and specific causes of GRFS failure. Our retrospective analysis from the Severe Aplastic Anemia Working Party of the European Society for Blood and Marrow Transplantation included 479 patients with idiopathic SAA who underwent allo-HSCT in two conventional situations: i) upfront allo-HSCT from a matched related donor (MRD) (upfront cohort), and ii) allo-HSCT for relapsed or refractory SAA (rel/ref cohort). Relevant events for GRFS calculation included graft failure, grade 3-4 acute GvHD, extensive chronic GvHD, and death. In the upfront cohort (n=209), 5-year GRFS was 77%. Late allo-HSCT (i.e., >6 months after SAA diagnosis) was the main poor prognostic factor, specifically increasing the risk of death as the cause of GRFS failure (hazard ratio [HR]=4.08; 95% confidence interval [CI]: 1.41-11.83; P=0.010). In the rel/ref cohort (n=270), 5-year GRFS was 61%. Age was the main factor significantly increasing the risk of death (HR=1.04; 95% CI: 1.02-1.06; P<0.001), acute GvHD (HR=1.03; 95% CI: 1.00-1.07; P=0.041), and chronic GvHD (HR=1.04; 95% CI: 1.01-1.08; P=0.032) as the cause of GRFS failure. GRFS after upfront MRD allo-HSCT was very good, notably with early allo-HSCT, confirming that younger patients with an MRD should be transplanted immediately. GRFS was worse in cases of salvage allo-HSCT, most notably in older patients, questioning the utility of allo-HSCT earlier in the disease course.
  • No Thumbnail Available
    Item
    GVHD and Relapse Free Survival (GRFS) After Allogeneic Transplantation for Idiopathic Severe Aplastic Anemia: An Analysis from the Saawp Data Quality Initiative Program of EBMT
    (2020) Devillier, Raynier; Eikema, Dirk-Jan; Bosman, Paul; Dufour, Carlo; Aljurf, Mahmoud; Wu, Depei; Maschan, Alexei; Afanasyev, Boris; Veelken, Joan Hendrik; Collin, Matthew; Snowden, John; Bertrand, Yves; Ganser, Arnold; Sykora, Karl-Walter; Gibson, Brenda E.; Maertens, Johan; Itala-Remes, Maija; Biondi, Andrea; Cornelissen, Jan; Bornhauser, Martin; Araujo, Mercedes Colorado; Ozdogu, Hakan; Risitano, Antonio; de la Tour, Regis Peffault; 0000-0002-8902-1283; AAD-5542-2021